The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance).
 
Mark Jesus Mendoza Magbanua
No Relationships to Disclose
 
Oleksandr Oleksandr Savenkov
No Relationships to Disclose
 
Erik Asmus
No Relationships to Disclose
 
Karla V. Ballman
Consulting or Advisory Role - ARIAD; Medtronic; Takeda
Patents, Royalties, Other Intellectual Property - Immune enrichment signature for response to trastuzumab in HER2+ breast cancer (Inst); Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Janssen Oncology; Lilly
 
Janet H Scott
No Relationships to Disclose
 
John Park
No Relationships to Disclose
 
Maura N. Dickler
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Consulting or Advisory Role - AstraZeneca; Celldex; Genentech/Roche; Hengrui Pharmaceutical; Lilly; Merrimack; Novartis; Pfizer; Puma Biotechnology; Syndax; TapImmune Inc.
Research Funding - Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst)
 
Ann H. Partridge
No Relationships to Disclose
 
Lisa A. Carey
Research Funding - Immunomedics (Inst); Innocrin Pharma (Inst); Syndax (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
 
Eric P. Winer
Stock and Other Ownership Interests - Verastem
Honoraria - Carrick Therapeutics; Genentech/Roche; GlaxoSmithKline; InfiniteMD; Jounce Therapeutics; Jounce Therapeutics; Lilly; Tesaro
Consulting or Advisory Role - InfiniteMD; Leap Therapeutics
Research Funding - Genentech (Inst)
 
Hope S. Rugo
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi